Join
Live feed
·
PRReleasevia Quantisnow
Lexeo Therapeutics Inc. logo

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

ByQuantisnow·Wall Street's wire, on your screen.
LXEO· Lexeo Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXEO (Lexeo Therapeutics Inc.) and more on Quantisnow.